According to the report of DelveInsight "Myasthenia Gravis (MG) Market Insights, Epidemiology and Market Forecast-2027", estimates suggest that there were XXXX prevalent cases of Myasthenia Gravis in 2016 in 7MM. These prevalent cases are further expected to increase and reach up to XXXX cases by 2027.

1. DelveInsight © 2018 | All rights reserved
Myasthenia Gravis –
Market Insight,
Epidemiology and
Market Forecast

2. i
ii
Myasthenia gravis (MG) is an
autoimmune syndrome caused by the
failure of neuromuscular transmission,
which results from the binding of
autoantibodies to proteins involved in
signaling at the neuromuscular junction
(NMJ).
These proteins include the nicotinic
Acetyl Cholinesterase (AChR) or, less
frequently, a muscle-specific tyrosine
kinase (MuSK).
Definition
DelveInsight © 2018 | All rights reserved

3. Overview of pathophysiology,
various diagnostic approaches &
treatment algorithm including
detailed chapters for marketed
products and emerging therapies
Historical as well as
forecasted epidemiology in
7MM covering the United
States, EU5 (Germany,
Spain, Italy, France and
United Kingdom) and Japan
from 20172028
Detailed Market size by
therapies, covering the United
States, EU5 (Germany, Spain,
Italy, France and United
Kingdom) and Japan from 2017-
2028
Pipeline analysis across different stages of
development (Phase III & Phase II), different
emerging trends and comparative analysis
of pipeline products with detailed clinical
profiles, key cross -competition, launch
date along with product development
activities
Detailed historical & forecasted
market covering the United
States, EU5 and Japan countries
from 2017-2028
Report Key Insights
DelveInsight © 2018 | All rights reserved

4. Japan had the lowest prevalent population of Myasthenia Gravis in 2017 with
~ 14,985 cases
Among the European countries, Spain had the highest prevalent population
of Myasthenia Gravis with ~ 15,275 cases, followed by Germany with
around 12,400 cases in 2017. France had the lowest prevalent pool of
Myasthenia Gravis in 2017
United States accounts for the highest prevalent population of Myasthenia
Gravis, followed by EU5 and Japan
DelveInsight estimates suggest that there were ~129,267 prevalent cases of
Myasthenia Gravis in 2017 in 7MM. These prevalent cases are further
expected to increase and reach up to XXXX cases by 2028
0
4
0
3
0
2
0
1
Myasthenia Gravis Epidemiology
DelveInsight © 2018 | All rights reserved

5. Graphical Representation of Myasthenia Gravis
Epidemiology Prevalent Cases of Myasthenia
Gravis in 7MM (2017-2028)
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
US Germany France Spain Itly UK Japan
PopulationinNumbers(n)
DelveInsight © 2018 | All rights reserved

6. The market size of Myasthenia
Gravis shall experience a positive
growth during the forecast period
(2018-2028)
With the launch of upcoming
therapies, the market size shall
increase significantly during
forecast period (2018-2028)
Although Corticosteroids have
been proven to be very effective
and used as a first line of therapy
for Myasthenia Gravis since last
decade, the related adverse
events hampers the quality of life
of the patients
Various monoclonal antibodies and
Immunoglobulin are been
investigated in late phase of
development to treat MG, so the
market is expected to change in the
coming years soon after the
approval of these biologics.
Various research and development
projects related to diagnosis and
novel treatments, will certainly
create a positive impact on the MG
market in upcoming years
Market Size

7. Emerging Drugs & Companies
DRUGS
COMPANIES
DelveInsight © 2018 | All rights reserved

8. COMPLETE INFORMATION
FOR COMPLETE INFORMATION PLEASE CLICK BELOW
OR
WRITE TO US AT
INFO@DELVEINSIGHT.COM
DelveInsight © 2018 | All rights reserved
Click here

9. Vision
“Insight across the value chain” to
help organizations make
important business decisions
through the use and analysis of
actionable market intelligence.
DelveInsight,
Market Research and consulting
firm, provides end to end
comprehensive solutions to the
Life Science Industry. We help
our customers in best decision
making through our expertise in
research & analysis and comes
out with unmatched data &
forecasts
Mission
To be the most trusted marketing
research firm & business co nsulting
firm worldwide. To be a renowned
and premier data driven solution
providers among Pharma & Biotech
companies
DelveInsight © 2018 | All rights reserved
About DelveInsight

10. Asset
Prioritization
Brand
Optimization
Portfolio
expansion
access over
3000+ reports
Therapeutic
Assessment
Drug Sales
Forecast
Indication
Forecast
Clinical
Trials
Tracking
Competitive
landscape
Clinical
Trials
Trends
Analysis
Physicians &
Patients
Perception
KOLs
API
Market &
Pipeline
Epidemiolo
gy
Market
Access
Partnershi
p
Services Offered at DelveInsight
DelveInsight © 2018 | All rights reserved

11. Contact Us:
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight
DelveInsight © 2018 | All rights reserved